Application of eligibility criteria from DAPA-HF, EMPEROR-Reduced, and PARADIGM-HF trials to a population with heart failure with reduced ejection fraction at a specialized cardiology Clinic in Medellin, Colombia: A Retrospective Cohort Study
ABSTRACT: Introduction: The evidence for the pharmacological treatment of heart failure is based on randomized clinical trials with strict inclusion and exclusion criteria. Objectives: To evaluate the proportion of patients with chronic heart failure from an outpatient cohort who would be eligible f...
- Autores:
-
González Franco, Juliana
Caicedo Espinosa, Javier Eduardo
Cardona Tobón, Carolina
Jaramillo Jara, Natalia
Aguilar Molina, Oswaldo
Jaimes Barragán, Fabian
Saldarriaga Giraldo, Clara Ines
- Tipo de recurso:
- Tesis
- Fecha de publicación:
- 2023
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/35809
- Acceso en línea:
- https://hdl.handle.net/10495/35809
- Palabra clave:
- Insuficiencia cardiaca
Heart failure
Ensayos clínicos controlados aleatorios como asunto
Randomized controlled trials as topic
Determinación de la elegibilidad
Eligibility determination
https://id.nlm.nih.gov/mesh/D006333
https://id.nlm.nih.gov/mesh/D016032
https://id.nlm.nih.gov/mesh/D004608
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by/4.0/
| Summary: | ABSTRACT: Introduction: The evidence for the pharmacological treatment of heart failure is based on randomized clinical trials with strict inclusion and exclusion criteria. Objectives: To evaluate the proportion of patients with chronic heart failure from an outpatient cohort who would be eligible for the trials DAPA-HF, EMPEROR-reduced, and PARADIGM-HF, and to determine potential differences between study populations. Methods: Through revision of medical records, we calculated the proportion of patients who would have been eligible for each study and evaluated the incidence of heart failure hospitalizations and all-cause mortality during this period. Results: A total of 446 patients were included in the cohort. Approximately 75% would be ineligible for the trials, mainly because of their comorbidities. Ineligible patients had a higher all-cause mortality, but a similar incidence of hospitalization. Conclusion: Approximately 1 in 4 patients from a heart failure clinic in Medellin, Colombia would meet the eligibility criteria for the DAPA-HF, EMPEROR-reduced, and PARADIGM-HF trials. These findings highlight the need to complement randomized clinical trials with real-world data. |
|---|
